TWI282735B - Combination and pharmaceutical formulation for the treatment of HBV infection - Google Patents

Combination and pharmaceutical formulation for the treatment of HBV infection Download PDF

Info

Publication number
TWI282735B
TWI282735B TW089122670A TW89122670A TWI282735B TW I282735 B TWI282735 B TW I282735B TW 089122670 A TW089122670 A TW 089122670A TW 89122670 A TW89122670 A TW 89122670A TW I282735 B TWI282735 B TW I282735B
Authority
TW
Taiwan
Prior art keywords
combination
patent application
pharmaceutical formulation
item
bms
Prior art date
Application number
TW089122670A
Other languages
English (en)
Chinese (zh)
Inventor
Nathaniel A Brown
Lynn D Condreay
Marc Rubin
Douglas Fraser Gray
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Application granted granted Critical
Publication of TWI282735B publication Critical patent/TWI282735B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Packages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW089122670A 1999-10-29 2000-10-27 Combination and pharmaceutical formulation for the treatment of HBV infection TWI282735B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/429,863 US6432966B2 (en) 1999-10-29 1999-10-29 Antiviral combinations

Publications (1)

Publication Number Publication Date
TWI282735B true TWI282735B (en) 2007-06-21

Family

ID=23705033

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089122670A TWI282735B (en) 1999-10-29 2000-10-27 Combination and pharmaceutical formulation for the treatment of HBV infection

Country Status (10)

Country Link
US (1) US6432966B2 (cg-RX-API-DMAC7.html)
EP (1) EP1225904B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003512421A (cg-RX-API-DMAC7.html)
AR (1) AR026255A1 (cg-RX-API-DMAC7.html)
AT (1) ATE273012T1 (cg-RX-API-DMAC7.html)
AU (1) AU1042701A (cg-RX-API-DMAC7.html)
DE (1) DE60012961T2 (cg-RX-API-DMAC7.html)
ES (1) ES2225245T3 (cg-RX-API-DMAC7.html)
TW (1) TWI282735B (cg-RX-API-DMAC7.html)
WO (1) WO2001030329A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001229775A1 (en) * 2000-02-29 2001-09-12 Bristol-Myers Squibb Company Low dose entecavir formulation and use
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
US8168568B1 (en) * 2003-03-10 2012-05-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Combinatorial therapy for protein signaling diseases
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1抗原決定位胜肽及含此胜肽的疫苗
CN102552210B (zh) * 2012-01-10 2013-12-11 四川海思科制药有限公司 一种恩替卡韦胶囊组合物及其制备方法
KR20170132327A (ko) * 2015-04-07 2017-12-01 스프링 뱅크 파마슈티칼스, 인크. Hbv 감염의 치료를 위한 조성물 및 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9800452D0 (sv) * 1998-02-13 1998-02-13 Medivir Ab Antivirals
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5206244A (en) 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
ATE131730T1 (de) 1991-05-16 1996-01-15 Glaxo Group Ltd Nukleosidanalogen enthaltende antiviren- zubereitungen
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
EP0988042B1 (en) * 1997-04-15 2008-01-09 Advanced Viral Research Corp. Combination of product r and an antiviral agent in the therapy of hiv infections
AU738472B2 (en) * 1997-09-25 2001-09-20 Cornell Research Foundation Inc. Method for inhibiting development of liver cancer and increasing survival in chronic hepadnavirus infection

Also Published As

Publication number Publication date
DE60012961T2 (de) 2005-08-18
DE60012961D1 (de) 2004-09-16
EP1225904A2 (en) 2002-07-31
ATE273012T1 (de) 2004-08-15
ES2225245T3 (es) 2005-03-16
US20020002180A1 (en) 2002-01-03
EP1225904B1 (en) 2004-08-11
AR026255A1 (es) 2003-02-05
JP2003512421A (ja) 2003-04-02
US6432966B2 (en) 2002-08-13
WO2001030329A2 (en) 2001-05-03
AU1042701A (en) 2001-05-08
WO2001030329A3 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
US11072648B2 (en) Mast cell stabilizers for treatment of fever
JP6196041B2 (ja) 大うつ病を有する患者において減量療法を提供する方法
JP2006511538A (ja) 非ヌクレオシド系逆転写酵素阻害剤(nnrti)とプロテアーゼ阻害剤などのシトクロムp450の阻害剤とを含む組み合わせの使用
WO2008091704A2 (en) Treatment of cushing's syndrome and autism
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
KR100413312B1 (ko) 항바이러스 복합약제
TW200534852A (en) 4-methylpyrazole formulations for inhibiting ethanol intolerance
US6432966B2 (en) Antiviral combinations
EP2830605A1 (en) A combination medicament comprising phenylephrine and paracetamol
JP6042886B2 (ja) 早漏症治療用の薬学組成物
US20110301199A1 (en) Compositions and methods for treating myelodysplastic syndrome
US12303503B1 (en) Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain
RU2842683C1 (ru) Фармацевтическая комбинация осельтамивира, парацетамола, источника витамина с и блокатора гистаминовых рецепторов
ZA200207701B (en) Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug.
EP1933823B1 (en) Pharmaceutical composition on basis of reverse transcriptase inhibitor and meldonium
RU2719376C1 (ru) Лекарственное средство седативного и миорелаксантного действия
RU106840U1 (ru) Диспергируемая в воде лекарственная таблетка противотуберкулезного действия
HK40011695A (en) Norketotifen for treatment of hypercytokinemia and viral infections
HK40011695B (en) Norketotifen for treatment of hypercytokinemia and viral infections
WO2013019220A1 (en) Compositions and methods for treating myelodysplastic syndrome
WO2013019222A1 (en) Compositions and methods for treating myelodysplastic syndrome
MXPA01009885A (en) Viral treatment
MXPA01009889A (en) Thiadiazolyl urea or thiourea derivatives for antiviral treatment
JPS6148482B2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees